New York, NY – Long-term data from a landmark international trial show about half of patients with metastatic melanoma treated with a combination of immune checkpoint inhibitors survive cancer-free for 10 years or more, according to a new report from Weill Cornell Medicine and Dana-Farber Cancer Center investigators and their...
Latest News
The suspicion that something was wrong started when the 1-year-old girl’s parents noticed she had trouble holding up her head. It was just the first of what would be many missed developmental milestones. By the time she was 8, the little girl still couldn’t sit up on her own, hold...
TORONTO, Canada — The World Ovarian Cancer Coalition announced that a groundbreaking international study, “Experiences of Women with Ovarian Cancer in 22 Low- and Middle- Income Countries (Every Woman Study™ LMIC): a Cross-sectional Study,” published today in The Lancet Obstetrics, Gynaecology, & Women’s Health, is the very first comprehensive study capturing...
OKLAHOMA CITY, Okla. – A pioneering research study published today in Cell Metabolism details how the hormone FGF21 (fibroblast growth factor 21) can reverse the effects of fatty liver disease in mice. The hormone works primarily by signaling the brain to improve liver function. University of Oklahoma researcher Matthew Potthoff,...
MIAMI, FLORIDA – The treatment landscape for acute myeloid leukemia (AML) is evolving rapidly, as research discoveries at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and other academic cancer centers advance new, more effective therapies for this aggressive blood cancer. “We’ve seen more progress...
DALLAS, Texas — Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage oncology company leveraging its proprietary RADR® artificial intelligence (AI) platform to accelerate drug discovery, today announced that the European Patent Office (EPO) has issued a notice of allowance for a composition of matter patent covering its drug candidate LP-284. This patent, expected...
Dallas — Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR® artificial intelligence (“AI”) and machine learning (“ML”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, announced that Lantern management and employees will be presenting at three upcoming events: Rare...
Independent research from Johns Hopkins validates Lantern’s data used to secure the FDA Rare Pediatric Disease Designation for LP-184 in ATRT and supports planned pediatric clinical trial DALLAS, Texas -Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging advanced AI and machine learning to transform the cost, pace, and...
RESEARCH TRIANGLE PARK, N.C. — RTI International, a nonprofit research institute and leading international development organization, joins the Lao People’s Democratic Republic (Lao PDR), World Health Organization, and the U.S. Agency for International Development (USAID) in celebrating Lao PDR’s achievement of eliminating lymphatic filariasis as a public health problem. Also known as elephantiasis, lymphatic filariasis...
Researchers have analysed image and genomic data from the UK Biobank to find insights into rare diseases of the human eye. These include retinal dystrophies – a group of inherited disorders affecting the retina – which are also the leading cause of blindness certification in working-age adults. The retina is...